Prime Medicine Q2 net loss $55.3M; FDA clears PM359 for CGD Phase 1/2 trial

Prime Medicine, Inc.

2024-Q2 EPS reported -$0.90 revenue$591,000

FDA cleared IND for PM359 (Prime Editor for chronic granulomatous disease); Phase 1/2 trial initiating, initial data expected 2025.
Net loss $55.3M vs $42.4M YoY; R&D expenses $43.1M up from $34.6M; G&A $12.6M vs $10.7M.
Cash, equivalents, investments & restricted cash $176.4M as of June 30, 2024 (up from $135.2M Dec 31, 2023).
Promoted Mohammed Asmal, M.D., Ph.D. to Chief Medical Officer, effective immediately; he was SVP Head of Clinical since 2022.
Pipeline milestones: liver IND/CTA expected H2 2025–H1 2026; ocular candidate nomination for RHO-RP in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.